Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia

Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Retina (Philadelphia, Pa.) Jg. 29; H. 8; S. 1062
1. Verfasser:	Cohen, Salomon Y
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.09.2009
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Humans Myopia, Degenerative - complications Myopia, Degenerative - drug therapy Ranibizumab Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects
ISSN:	1539-2864, 1539-2864
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!